Nektar Therapeutics (NKTR) EBITDA (2010 - 2026)

Nektar Therapeutics' EBITDA history runs 17 years deep, the most recent figure standing at -$39.1 million for Q1 2026.

• In Q1 2026, EBITDA rose 12.31% year-over-year to -$39.1 million; the TTM figure through Mar 2026 stood at -$134.6 million (down 17.77% YoY), while the FY2025 annual figure was -$140.1 million, down 33.18% from the prior year.
• EBITDA for Q1 2026 stood at -$39.1 million, down from -$27.7 million in the prior quarter.
• The five-year high for EBITDA was $14.3 million in Q4 2024, with the low at -$152.8 million in Q2 2022.
• The 5-year median for EBITDA is -$44.5 million (2025), against an average of -$54.4 million.
• The sharpest annual moves came in 2024 and 2025: EBITDA soared 142.82% in 2024, then sank 292.81% in 2025.
• Nektar Therapeutics' EBITDA stood at -$52.5 million in 2022, then soared by 36.13% to -$33.5 million in 2023, then jumped by 142.82% to $14.3 million in 2024, then tumbled by 292.81% to -$27.7 million in 2025, then tumbled by 41.17% to -$39.1 million in 2026.
• Business Quant data shows NKTR's EBITDA at -$39.1 million in Q1 2026, -$27.7 million in Q4 2025, and -$31.7 million in Q3 2025.